FY2028 Earnings Estimate for PRCT Issued By Leerink Partnrs

PROCEPT BioRobotics Co. (NASDAQ:PRCT) – Equities researchers at Leerink Partnrs boosted their FY2028 EPS estimates for shares of PROCEPT BioRobotics in a research report issued on Monday, October 28th. Leerink Partnrs analyst M. Kratky now anticipates that the company will earn $0.12 per share for the year, up from their prior forecast of $0.10. The consensus estimate for PROCEPT BioRobotics’ current full-year earnings is ($1.88) per share.

Other equities research analysts also recently issued reports about the stock. TD Cowen upped their price objective on shares of PROCEPT BioRobotics from $75.00 to $99.00 and gave the company a “buy” rating in a report on Monday, September 16th. Bank of America upped their price target on shares of PROCEPT BioRobotics from $80.00 to $94.00 and gave the company a “buy” rating in a research note on Thursday, August 22nd. Wells Fargo & Company lifted their price objective on shares of PROCEPT BioRobotics from $67.00 to $69.00 and gave the company an “overweight” rating in a research note on Friday, August 2nd. Truist Financial restated a “buy” rating and set a $105.00 target price (up previously from $95.00) on shares of PROCEPT BioRobotics in a research report on Wednesday. Finally, Piper Sandler reiterated an “overweight” rating and issued a $75.00 price target on shares of PROCEPT BioRobotics in a research report on Tuesday, October 8th. Five research analysts have rated the stock with a buy rating, According to MarketBeat, the stock has a consensus rating of “Buy” and an average target price of $88.40.

PROCEPT BioRobotics Stock Down 3.3 %

PRCT stock opened at $90.00 on Wednesday. The stock has a fifty day moving average of $77.20 and a 200-day moving average of $67.91. PROCEPT BioRobotics has a fifty-two week low of $24.91 and a fifty-two week high of $99.34. The company has a market capitalization of $4.67 billion, a price-to-earnings ratio of -46.15 and a beta of 1.03. The company has a debt-to-equity ratio of 0.20, a quick ratio of 6.49 and a current ratio of 7.51.

PROCEPT BioRobotics (NASDAQ:PRCT) last posted its quarterly earnings data on Monday, October 28th. The company reported ($0.40) EPS for the quarter, beating the consensus estimate of ($0.49) by $0.09. PROCEPT BioRobotics had a negative return on equity of 37.85% and a negative net margin of 58.73%. The business had revenue of $58.40 million for the quarter, compared to the consensus estimate of $53.30 million. During the same quarter in the prior year, the business earned ($0.51) earnings per share. PROCEPT BioRobotics’s revenue for the quarter was up 66.4% on a year-over-year basis.

Insiders Place Their Bets

In other news, CEO Reza Zadno sold 288,461 shares of the business’s stock in a transaction on Wednesday, October 30th. The shares were sold at an average price of $91.00, for a total transaction of $26,249,951.00. Following the completion of the transaction, the chief executive officer now directly owns 258,445 shares in the company, valued at $23,518,495. The trade was a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. In related news, CEO Reza Zadno sold 288,461 shares of the stock in a transaction on Wednesday, October 30th. The stock was sold at an average price of $91.00, for a total value of $26,249,951.00. Following the sale, the chief executive officer now owns 258,445 shares in the company, valued at approximately $23,518,495. This trade represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, Director Antal Rohit Desai sold 35,220 shares of the business’s stock in a transaction dated Tuesday, September 3rd. The stock was sold at an average price of $76.12, for a total value of $2,680,946.40. Following the transaction, the director now owns 23,963 shares of the company’s stock, valued at approximately $1,824,063.56. The trade was a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 468,353 shares of company stock worth $40,196,366 in the last three months. 17.40% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

Several institutional investors have recently modified their holdings of PRCT. Values First Advisors Inc. purchased a new position in PROCEPT BioRobotics in the 3rd quarter worth approximately $27,000. Mark Sheptoff Financial Planning LLC bought a new stake in shares of PROCEPT BioRobotics during the 2nd quarter worth $36,000. Quest Partners LLC lifted its holdings in shares of PROCEPT BioRobotics by 2,492.3% during the 2nd quarter. Quest Partners LLC now owns 674 shares of the company’s stock worth $41,000 after acquiring an additional 648 shares during the last quarter. Nisa Investment Advisors LLC grew its position in PROCEPT BioRobotics by 178.3% in the third quarter. Nisa Investment Advisors LLC now owns 1,113 shares of the company’s stock worth $89,000 after acquiring an additional 713 shares in the last quarter. Finally, Sentry Investment Management LLC bought a new position in PROCEPT BioRobotics in the third quarter valued at $120,000. 89.46% of the stock is currently owned by institutional investors.

About PROCEPT BioRobotics

PROCEPT BioRobotics Corporation, a surgical robotics company, focuses on developing transformative solutions in urology in the United States and internationally. The company develops, manufactures, and sells AquaBeam Robotic System, an image-guided, surgical robotic system for use in minimally invasive urologic surgery with a focus on treating benign prostatic hyperplasia (BPH).